Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03277365

MyGeneRank: A Digital Platform for Next-Generation Genetic Studies

Many conditions affecting health are caused by a combination of environment, behaviors, and genes. While individuals can alter some factors in their lives to reduce the chances of developing different diseases (e.g., not smoking cigarettes), the contribution from genetic risk encoded by DNA remains with people throughout their lives. Scientists are still trying to determine the entirety of genetic factors that influence disease, but for some conditions it has been shown that the factors identified thus far can begin to identify people at high to low genetic risk. Looking across the genome, scientists can calculate a cumulative genetic risk score - which can be used to rank genetic risk compared to other worldwide populations.

The goal of this study is to determine how genetic risk influences health decisions and other things that can be controlled in life. The first genetic risk score is calculated for coronary heart disease (CAD). CAD ultimately leads to heart attacks, heart failure and sometimes sudden cardiac death and is the main reason heart disease remains as the number one cause of death worldwide. Other researchers have shown that this genetic risk score can be used to identify people with low, intermediate, and high risk for coronary heart disease. It has also been shown that the use of statins (cholesterol lowering drugs) provides greater benefit and protection against heart attack for people with high genetic risk for coronary artery disease.

Leveraging the Apple ResearchKit and the ResearchKit linked 23andMe API, customers of 23andMe are able to provide researchers access to their genomic data. Participants will use the ResearchKit app to provide consent, view study information, answer surveys, and contact the study team.

Participants will be asked to complete 3 surveys. One before viewing genetic risk scores, one immediately after viewing scores, and one 6 months after viewing scores.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Scripps Translational Science Institute

La Jolla, California, 92037, United States

Location status: Recruiting

Location contact

Emily Spencer, PhD

CONTACT

[email protected]

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Customer of 23andMe willing to share their 23andMe data
  • User of Apple mobile device

Exclusion criteria

  • Under 18 years old

Treatment and study plan

Receive genetic risk information

Other

Risk scores are provided by ResearchKit app.

Primary outcomes

  1. Initiation of Statin Therapy

    Time frame: 6 months

    Participant begins taking Statin as indicated by survey.

Study contacts

Contact information is provided by the study sponsor or research team.

Jennifer Wagner, RN

CONTACT

[email protected]

858-784-2028

Sponsors and collaborators

Lead sponsor

Scripps Translational Science Institute

Other

Registry information

Important dates

Study start
2017
Primary completion
2026
Study completion
2030
First posted
Sep 11, 2017
Registry last updated
Apr 17, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.